This is a positive product launch catalyst for Dr. Reddy's, establishing first-mover advantage in the Canadian generic semaglutide market. Monitor for subsequent launches in other G7 markets and any revenue guidance updates in upcoming quarterly filings. The GLP-1 franchise build-out supports long-term growth narrative.
RDY drugs
RDY drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 15 $13.61entry
- T+1 · 6mo ago −0.07%α −0.01% · $13.60
- T+5 · 6mo ago −0.07%α −1.04% · $13.60
- T+20 · 5mo ago −2.06%α −4.18% · $13.33
- T+60 · 3mo ago −8.52%α −13.04% · $12.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's launched its generic Semaglutide Injection in Canada on May 15, 2026, following Health Canada approval on April 28, 2026. The company is the first to receive approval for a generic semaglutide in Canada, which is also the first G7 country to authorize the product. This expands Dr. Reddy's GLP-1 portfolio and demonstrates its ability to rapidly commercialize complex peptides.
Key Facts
- Dr. Reddy's launched generic Semaglutide Injection in Canada on May 15, 2026.
- Health Canada Notice of Compliance (NOC) received on April 28, 2026.
- Dr. Reddy's is the first company to receive Health Canada approval for generic Semaglutide Injection.
- Canada is the first G7 country to grant market authorization for generic Semaglutide Injection.
- Product is indicated for once-weekly treatment of type 2 diabetes in adults.
- Available in 2 mg/pen and 4 mg/pen strengths (1.34 mg/ml concentration).
- Follows recent launch in India under brand name Obeda.
- CEO Erez Israeli highlighted GLP-1 therapies as a key focus area with active expansion across global markets.
Financial Impact
No specific revenue or financial figures disclosed in the filing. The launch expands addressable market in a high-growth GLP-1 category, but near-term financial contribution is unquantifiable from this filing alone.
Risk Factors
- Competitive response from Novo Nordisk or other generic entrants could erode market share and pricing.
- Regulatory or supply chain challenges in scaling production for additional markets.
- Semaglutide is indicated only for type 2 diabetes in Canada; obesity indication not covered by this launch.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000334 |
| Document: 0001575872-26-000334-index.html | 0001575872-26-000334 |
| Document: 0001575872-26-000334.txt | 0001575872-26-000334 |
Track record
73 reports on RDY
7 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers